News& Press Releases

Excited to share our contribution to the development of a groundbreaking PET ligand for imaging of non-AD tauopathies! 

Offspring Biosciences offers support services for businesses in preclinical and clinical drug development. – We help our customers make new drugs available to patients faster, safer, and at a lower cost, says Anders Dahlstrand, CEO of the company. Offspring Biosciences operates in the rapidly growing CRO industry (Contract Research Organization) and assists pharmaceutical and biotech companies by conducting preclinical and clinical studies required for regulatory approvals. O

New publication, “Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein” together with Karolinska Institutet, Andrea Varrone research group. The approach used in this study also shows that TMAs are a useful tool for the evaluation of ligands in tissue from different proteinopathies, using both fluorescence and autoradiographic assays https://doi.org/10.1016/j.brainres.2020.147131 The neuropathological hallmark o

Most projects are closed down before the drug has reached the market. With the support of Offspring Bioscience's unique expertise in tissue analysis, pharmaceutical companies significantly improve the odds of success ​ "Our unique ability to plan and carry out such analyses is based on the experience we have built up over a long period of time through our work on pharmaceutical projects in the pharmaceutical industry. With efficient methods and refined analytical techniques,